The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Cystadenoma, Serous

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cystadenoma, Serous


High impact information on Cystadenoma, Serous


Chemical compound and disease context of Cystadenoma, Serous


Biological context of Cystadenoma, Serous


Anatomical context of Cystadenoma, Serous


Gene context of Cystadenoma, Serous


Analytical, diagnostic and therapeutic context of Cystadenoma, Serous


  1. Carcinoembryonic antigen in human ovarian neoplasms. Marchand, A., Fenoglio, C.M., Pascal, R., Richart, R.M., Bennett, S. Cancer Res. (1975) [Pubmed]
  2. Contrast-enhanced endoscopic ultrasonography in pancreatic diseases: a preliminary study. Hirooka, Y., Goto, H., Ito, A., Hayakawa, S., Watanabe, Y., Ishiguro, Y., Kojima, S., Hayakawa, T., Naitoh, Y. Am. J. Gastroenterol. (1998) [Pubmed]
  3. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Brustmann, H. Gynecol. Oncol. (2004) [Pubmed]
  4. Clinical and pathologic correlation of endometrial cavity fluid detected by ultrasound in the postmenopausal patient. Carlson, J.A., Arger, P., Thompson, S., Carlson, E.J. Obstetrics and gynecology. (1991) [Pubmed]
  5. Telomerase activity is a useful marker to distinguish malignant pancreatic cystic tumors from benign neoplasms and pseudocysts. Yeh, T.S., Cheng, A.J., Chen, T.C., Jan, Y.Y., Hwang, T.L., Jeng, L.B., Chen, M.F., Wang, T.C. J. Surg. Res. (1999) [Pubmed]
  6. Preoperative cyst fluid analysis is useful for the differential diagnosis of cystic lesions of the pancreas. Hammel, P., Levy, P., Voitot, H., Levy, M., Vilgrain, V., Zins, M., Flejou, J.F., Molas, G., Ruszniewski, P., Bernades, P. Gastroenterology (1995) [Pubmed]
  7. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Chodankar, R., Kwang, S., Sangiorgi, F., Hong, H., Yen, H.Y., Deng, C., Pike, M.C., Shuler, C.F., Maxson, R., Dubeau, L. Curr. Biol. (2005) [Pubmed]
  8. Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Tseng, J.F., Warshaw, A.L., Sahani, D.V., Lauwers, G.Y., Rattner, D.W., Fernandez-del Castillo, C. Ann. Surg. (2005) [Pubmed]
  9. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma. Lewandrowski, K.B., Southern, J.F., Pins, M.R., Compton, C.C., Warshaw, A.L. Ann. Surg. (1993) [Pubmed]
  10. Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. Gordon, J.D., Mesiano, S., Zaloudek, C.J., Jaffe, R.B. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  11. High concentrations of inhibin A and inhibin B in ovarian serous cystadenoma: relationship with oestradiol and nitric oxide metabolites. Reis, F.M., Faletti, A., Luisi, S., Bifulco, G., Cauci, S., Quadrifoglio, F., Dor, J., Petraglia, F. Mol. Hum. Reprod. (2000) [Pubmed]
  12. Virilizing serous cystadenoma. Beauchamp, P.J., Hughes, R.S., Schmidt, W.A. Obstetrics and gynecology. (1989) [Pubmed]
  13. Hemoperitoneum as a result of coital injury without associated vaginal injury. McColgin, S.W., Williams, L.M., Sorrells, T.L., Morrison, J.C. Am. J. Obstet. Gynecol. (1990) [Pubmed]
  14. High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid. Boss, E.A., Moolenaar, S.H., Massuger, L.F., Boonstra, H., Engelke, U.F., de Jong, J.G., Wevers, R.A. NMR in biomedicine. (2000) [Pubmed]
  15. A case of concurrent endometrial carcinoma, fallopian tube carcinoma and a benign right ovarian serous cystadenoma with tamoxifen therapy. Soltan, A.S., Hutcheson, R.B. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. (1997) [Pubmed]
  16. Hemorrhagic ovarian cysts in patients on anticoagulation therapy: CT findings. Wilbur, A.C., Goldstein, L.D., Prywitch, B.A. Journal of computer assisted tomography. (1993) [Pubmed]
  17. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases. Yamaguchi, K., Chijiiwa, K., Noshiro, H., Torata, N., Kinoshita, M., Tanaka, M. Hepatogastroenterology (1999) [Pubmed]
  18. Tumor-suppressing pathways in cystic pancreatic tumors. Gerdes, B., Wild, A., Wittenberg, J., Barth, P., Ramaswamy, A., Kersting, M., Lüttges, J., Klöppel, G., Bartsch, D.K. Pancreas (2003) [Pubmed]
  19. Molecular genetic analysis of ovarian serous cystadenomas. Cheng, E.J., Kurman, R.J., Wang, M., Oldt, R., Wang, B.G., Berman, D.M., Shih, I.e.M. Lab. Invest. (2004) [Pubmed]
  20. Esophagogastric varices due to arterioportal shunt in a serous cystadenoma of the pancreas in von Hippel-Lindau disease. Okuyama, M., Fujiwara, Y., Hayakawa, T., Shiba, M., Watanabe, T., Tominaga, K., Tamori, A., Oshitani, N., Higuchi, K., Matsumoto, T., Nakamura, K., Wakasa, K., Hirohashi, K., Ashida, S., Shuin, T., Arakawa, T. Dig. Dis. Sci. (2003) [Pubmed]
  21. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas. Halperin, R., Zehavi, S., Dar, P., Habler, L., Hadas, E., Bukovsky, I., Schneider, D. Eur. J. Gynaecol. Oncol. (2001) [Pubmed]
  22. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Wang, J., Lin, L., Parkash, V., Schwartz, P.E., Lauchlan, S.C., Zheng, W. Int. J. Cancer (2003) [Pubmed]
  23. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Choi, Y.L., Kim, S.H., Shin, Y.K., Hong, Y.C., Lee, S.J., Kang, S.Y., Ahn, G. Gynecol. Oncol. (2005) [Pubmed]
  24. A plasminogen activator from benign ovarian cystadenoma: partial purification and characterization. Cheung, A., Lau, H.K., Yuen, P. Thromb. Res. (1986) [Pubmed]
WikiGenes - Universities